非何杰金氏淋巴瘤市場：KOL 洞察

本報告考察了非何杰金氏淋巴瘤市場，並對目前和新興的治療方法進行了詳細分析。包含 CAR T 細胞療法、雙特異性抗體和 BTK 抑制劑的功效和未來潛力的重要見解。 也討論非何杰金氏淋巴瘤治療的最新趨勢、挑戰和進展，為醫療保健專業人員和研究人員提供有價值的資訊。

目錄

執行摘要

目前與未來的治療演算法

研究目的

CAR T 細胞療法

• 瀰漫性大 B 細胞淋巴瘤
  • Yescarta（axicabtagene ciloleucel，Gilead）、Bryanzi（lisocabtagene maraleucel，BMS）和 Kymriah（tisagenlecleucel、Novartis）
• 濾泡性淋巴瘤
  • Yescarta（axicabtagene ciloleucel，Gilead）、Bryanzi（lisocabtagene maraleucel，BMS）和 Kymriah（tisagenlecleucel，Novartis）
• 套細胞淋巴瘤
  • Tecartas（Brexacabtagene Autoleucel，Gilead）和 Breyanzi（Lysocabtagene Malaleucel，BMS）
• 下一代 CAR T 細胞療法
  • 主要見解摘要

作用於 T 細胞的雙特異性抗體（BsAb）

• 濾泡性淋巴瘤
  • Lunumio（mosnetuzumab，Roche）、Epkinly/Tepkinly（epcolitamab、AbbVie/Genmab）、Columvi（grofitamab，Roche）和 odronectamab（Regeneron）
• 瀰漫性大 B 細胞淋巴瘤
  • Epkinly/Tepkinly（epcolitamab、AbbVie/Genmab）、Columvi（grofitamab、Roche）、Lunsmio（mosnetuzumab、Roche）和 odronectamab（Regeneron）
• 套細胞淋巴瘤與邊緣區淋巴瘤
  • Epkinly/Tepkinly（epcolitamab、AbbVie/Genmab）、Columvi（grofitamab、Roche）、Lunsmio（mosnetuzumab、Roche）和 odronectamab（Regeneron）

抗體藥物偶聯物（ADC）

• 核准的藥物
  • Polyvy（polatuzumab vedotin，Roche）
  • Zinlonta（loncasuximab tesirin，ADC Therapeutics/Sobi）

單株抗體（mAb）

• 核准的藥物
  • Monjuvi/Minjuvi（tafasitamab、Incyte）

BCL-2 抑制劑（9）

• 研究藥物
  • Venclexta/Venclyxt（Venetoclax、AbbVie/Roche）

BTK 抑制劑（16）

• 核准的藥物（16）
  • Brukinsa（zanubrutinib，BeiGene）、Calquence（acalabrutinib，AstraZeneca）、Imbruvica（ibrutinib，AbbVie/J&J）和 Jaypirca（pirtobrutinib，Lilly）

未來治療趨勢

• 主要見解摘要

附錄

KOL報表

This Non-Hodgkin's Lymphoma (NHL) Therapy Trends report provides a detailed analysis of current and emerging therapies. It includes insights from leading Key Opinion Leaders (KOLs) on the efficacy and future potential of CAR T-cell therapy, bispecific antibodies, and BTK inhibitors. The report examines the latest trends, challenges, and advancements in NHL treatment, offering valuable information for healthcare professionals and researchers. It aims to inform on the evolving landscape of NHL management, supported by data-driven findings and expert opinions.

Table of Contents

Executive summary

Current and future treatment algorithms

Research objectives

CAR T-cell therapies

• Diffuse large B-cell lymphoma
  • Yescarta (axicabtagene ciloleucel; Gilead), Breyanzi (lisocabtagene maraleucel; BMS) and Kymriah (tisagenlecleucel; Novartis)
• Follicular lymphoma
  • Yescarta (axicabtagene ciloleucel; Gilead), Breyanzi (lisocabtagene maraleucel; BMS) and Kymriah (tisagenlecleucel; Novartis)
• Mantle cell lymphoma
  • Tecartus (brexucabtagene autoleucel; Gilead) and Breyanzi (lisocabtagene maraleucel; BMS)
• Next-generation CAR T-cell therapies
  • Key insights summary

T cell-engaging bispecific antibodies (BsAbs)

• Follicular lymphoma
  • Lunsumio (mosunetuzumab; Roche), Epkinly/Tepkinly (epcoritamab; AbbVie/Genmab), Columvi (glofitamab; Roche) and odronextamab (Regeneron)
• Diffuse large B-cell lymphoma
  • Epkinly/Tepkinly (epcoritamab; AbbVie/Genmab), Columvi (glofitamab; Roche), Lunsumio (mosunetuzumab; Roche), and odronextamab (Regeneron)
• Mantle cell lymphoma and marginal zone lymphoma
  • Epkinly/Tepkinly (epcoritamab; AbbVie/Genmab), Columvi (glofitamab; Roche), Lunsumio (mosunetuzumab; Roche) and odronextamab (Regeneron)

Antibody-drug conjugates (ADCs)

• Approved drugs
  • Polivy (polatuzumab vedotin; Roche)
  • Zynlonta (loncastuximab tesirine; ADC Therapeutics/Sobi)

Monoclonal antibodies (mAbs)

• Approved drugs
  • Monjuvi/Minjuvi (tafasitamab; Incyte)

BCL-2 inhibitors

• Pipeline drugs
  • Venclexta/Venclyxto (venetoclax; AbbVie/Roche)

BTK inhibitors

• Approved drugs
  • Brukinsa (zanubrutinib; BeiGene), Calquence (acalabrutinib; AstraZeneca), Imbruvica (ibrutinib; AbbVie/J&J) and Jaypirca (pirtobrutinib; Lilly)

Future treatment trends

• Key insights summary

Appendix

• KOL details
  • KOLs from North America
  • KOLs from Europe

KOL Bulletins